In a move widely viewed as a bad blow to India's biggest biotech, Pfizer ($PFE) has written off its $200 million upfront payment to India's Biocon ($BIOCON)--right along with all the licensing rights involved in their biosimilar insulin development deal.
India has invoked its compulsory licensing rules for the first time, allowing the domestic drugmaker Natco Pharma to make and sell a version of Bayer's cancer drug Nexavar--despite the fact that...
Bayer Healthcare said it expects Asia sales to grow to 11 billion euros by 2015, with 6 billion of that coming from the China region.
When Chris Hansen of "Dateline" shows up at the door, you know some predator is about to get very publicly busted.
Sanofi ($SNY) CEO Chris Viehbacher (photo) managed to parlay one personal appearance into a half-dozen different headlines. Development strategies? Check. M&A interest? Check. Job creation?...
AstraZeneca ($AZN) may buy out minority shareholders in its Indian unit, snapping up the 10% share it doesn't already own and delisting the company.
RusNano is now partnering with Domain Associates on a $760 million initiative that will invest in about 20 life sciences companies and construct a pharma manufacturing center in Russia to produce next-gen therapies.
GlaxoSmithKline ($GSK) and Japan's number three pharma company Daiichi Sankyo have created a joint venture to bring new treatments to the Japanese market.
You know how you've been hearing how CROs in China are expanding? Well, Newsummit Biopharma is the latest example of that trend. The Shanghai company has filed plans in the U.S. for an $80...
Bribery investigators are hardly barking up the wrong tree when it comes to pharmaceuticals.